Open Access

Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism

  • Yao Yao1,
  • Xiao-Bo Li2,
  • Wei Zhao3,
  • Yan-Yan Zeng1,
  • Hong Shen1,
  • Hua Xiang3 and
  • Hong Xiao1Email author
Lipids in Health and Disease20109:49

https://doi.org/10.1186/1476-511X-9-49

Received: 11 March 2010

Accepted: 19 May 2010

Published: 19 May 2010

Abstract

Background

The novel compound 1a is one of the isoflavone fatty acid esters. In order to investigate the anti-obesity effect of compound 1a and its potential mechanism of influence in adipocyte differentiation, Obese male C57BL/6J mice induced by high-fat diet (HFD) and rat preadipocytes (3T3-L1 cell) were used.

Methods

After 4-week HFD induction, the obese model was made successfully. After treatment with compound 1a, mice plasma biochemistry parameters were analyzed. In addition, mice hepatic tissue slice was observed. In in vitro research, 3T3-L1 cell differentiation by Oil-Red-O staining and adipocyte apoptosis was detected by flow cytometry.

Results

The in vivo results implied that compound 1a significantly decreased the body weight, white adipose tissue weight of obesity mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated HDL-C in serum(p < 0.05). The in vitro results suggested that compound 1a could significantly suppress the adipocyte viability and lipid accumulation in the differentiation of preadipocyte, and induce apoptosis in both preadipocytes and mature adipocytes(p < 0.05).

Conclusion

Compound 1a regulates serum lipid profiles, decreases adipose tissue mass and body weight gain by inducing adipocyte apoptosis in high fat diet induced mice. Thus, it may be used to treat obese patients with hypercholesterolemia and hypertriglyceridemia.

Background

Obesity, which results from a prolonged energy imbalance during which intake exceeds expenditure, is a rapidly growing epidemic in modernized world [1] and is a major risk factor for several serious chronic diseases, such as type 2 diabetes, cardiovascular disease, hypertension, stroke, asthma, and certain forms of cancer [2]. Considerable effort has been devoted to the discovery of anti-obesity drugs worldwide. Though there are dozens of potential targets for anti-obesity, only three agents, sibutramine (Reductil® or Meridia®), an appetite suppressant orlistat (Xenical®), an inhibitor of fat absorption and rimonaban, a CB1 antagonist, have been introduced into the market during recent years [3]. But several serious adverse effects of sibutramine, orlistat and rimonaban were reported in clinical practice, including gastrointestinal adverse effect and significant unfavorable effects on cardiovascular system [46]. The difficulty to lose excessive weight is tightly linked to the complexity and redundancy within lipid systems, which involve an intricate network of peripheral signals and neuronal circuits, constitute obstacles to seek effective potential targets for anti-obesity treatments [7]. In the peripheral organizations, the fat tissue plays an important role in maintaining the energy balance. It is not only an energy storage organ, but also a secretion one. It produces and secretes dozens of factors such as leptin, adiponectin, resistin, visfatin, tumor necrosis factor-α(TNF-α), and interleukin-6 (IL-6), which participate in the energy metabolism of adipose tissue itself and the whole body either in an auto/paracrine or an endocrine fashion [811]. Obesity is characterized by an increase in the number and size of adipocytes differentiated from fibloblastic preadipocytes in adipose tissues [12].

Adipocytes play a vital role in regulating adipose mass and obesity, in relation not only to lipid homeostasis and energy balance but also to secreting transcription factors [13]. 3T3-L1 cells have been served as well-established in vitro model to assess adipogenesis and adipocyte differentiation [14]. The programmed differentiation of preadipocytes into adipocytes involves several stages related to obesity [15]. For these reasons, many research efforts have been conducted in 3T3-L1 cells to search for new health benefit foods/agents for obesity or weight control. Potential therapeutic agents that inhibit adipogenesis or increase adipocyte death by apoptosis could be important tools in preventing obesity [16].

Isoflavones are found at high levels in soy plants and structurally similar to estrogens [17]. They are suggested to be a potential alternative to estrogen therapy in the treatment and prevention of menopausal symptoms, osteoporosis, breast cancer and cardiovascular disease. Genistein, daidzein, glycitein, formononetin and biochanin A are considered to be the most important and hence most studied isoflavone phytoestrogens [18, 19]. It is also reported that isoflavones have healthful benefits in human obesity and have a positive influence on plasma cholesterol [20].

Here in this paper we defined 4'-methoxy daidzein-7-fatty acid esters as compound 1a (Fig.1).
Figure 1

Structural formula of compound 1a.

We performed research to evaluate the anti- dyslipidemia effect of compound 1a and its potential mechanism in adipocyte differentiation.

Materials and methods

Material

Compound 1a was provided by China pharmaceutical university. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) were purchased from Gibco BRL of Invitrogen Corporation (Carlsbad, CA). Methylisobutylxanthine, hochest 33342 dye, MTT and Oil-Red-O were obtained from Sigma (St. Louis, MO). Dexamethasone was purchased from Xianju Pharmaceutical Co.Ltd (Zhejiang, China). Insulin was purchased from Wanbang Pharmaceutical Co.Ltd (Xuzhou, China). Leptin ELISA kit was obtained from Boster (Wuhan, China). Anannexin V-fluorescein isothiocyanate (FITC) Apoptosis kit was provided by KeyGene (Nanjing, China). All other reagents were of analytical grade.

Animals and diets

Fifty male C57BL/6J mice initially weighing 16.03 ± 1.22 g from Nanjing University Animal Center were used. The animals were housed in 12 h light/dark cycle (light on 7a.m.), temperature 22°C, and allowed adlibitum access to diet and water.

Animal groups

After one week's acclimatization period, 50 mice were divided randomly into two groups: the normal group (n = 10) were fed with low fat diet (LFD), whereas the experimental group (n = 40) were fed with high-fat diet (HFD).

After 4-week induction, the obese model was made successfully. The 40 obese mice were divided into four groups (n = 10/each group): model group, low dosage group (50 mg·kg-1 compound 1a), high dosage group (100 mg·kg-1 compound 1a) and control group (200 mg·kg-1 Inositol Hexanicotinate) respectively.

HFD composition

HFD was composed with 90.5% basal diet, 2% cholesterol, 0.5% propacil and 7% grease.

Adiminstration modality

Drugs were intragastric administration with suspension in olive oil (0.1 ml/10 g) at 9 A.M. The normal group and model group were administered only olive oil. After 4 weeks, animals were fasted overnight. Next day, blood samples were collected fast from the retroorbital sinus into tubes; serum was separated and stored at -80°C until analysis. Then animals were sacrificed by cervical dislocation and tissues were harvested, weighed, snap frozen in liquid nitrogen and stored at -80°C until use. All animal experiments were approved by the Institutional Animal Care and Use Committees of Nanjing Medical University, and followed National Research Council Guidelines.

Biochemical analysis

In serum, total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) were measured by Automatic Analyzer 7170A (Hitavhi, Jap.). Serum leptin was detected through leptin ELISA kit (Boster, China).

Histological analysis

The right lobe of rat liver was fixed in 10% phosphate-buffered formalin for one day and processed in a routine manner to generate 3 μm thick paraffin sections, which were stained with hematoxylin and eosin (HE) and subjected to microscopic examination.

Cell culture

3T3-L1 preadipocytes were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). After cell reached 80% confluence, the preadipocytes were induced with 1 mg·mL-1 insulin (Wanbang), 1 mmol·L-1 DEX (Xianju) and 0.5 mmol·L-1 MIX (Sigma) (MDI) in DMEM supplemented with 10% fetal bovine serum. After 48 h, the culture medium was replaced with DMEM supplemented with 10% fetal bovine serum and 1 mg·mL-1 insulin, which was switched to DMEM containing 10% fetal bovine serum 2 days later. Cytoplasmic triglyceride droplets were visible under the fluorescence microscope (Carl Ziess Axiovert 40 CFL). For the following experiments, preadipocytes and mature adipocytes were treated for 48 h. All compounds, stock solutions were prepared in DMSO and filter sterilized.

Cell Viability

All the tests were done in 96-well plates. For non-maturing preadipocyte experiments, cells were seeded (5 × 103 cells/well) and grown until they reached confluence, and then treated with the compounds or vehicle (DMSO). After the cells were treated with compound 1a for the 48 h, MTT (Sigma) solution 20 μL (0.5 mg·mL-1) was added into the cell culture medium, and the cells were incubated at 37°C and 5% CO2 for 4 h. The MTT formazan crystals were then dissolved with 150 μL DMSO and the absorbance in individual wells was determined at 570 nm by a microplate reader (Labsystems Multiskan Ascent). The inhibition of cell growth was evaluated by the MTT method by using triplicate assay. The inhibition ratio was calculated thorough the formula 1.
(1)

Oil-Red-O staining

For Oil-Red-O staining [21], cells were washed gently with phosphate buffered saline (PBS) twice, fixed with 3.7% fresh formaldehyde (Sigma) in PBS for 1 h at room temperature and stained with filtered Oil-Red-O (Sigma) solution (60% isopropanol and 40% water) for at least 1 h. After staining of lipid droplets with red, the Oil-Red-O staining solution was removed and the plates were rinsed with water and dried. Images of the stained lipid droplets were collected on a fluorescence microscope (Carl Ziess Axiovert 40 CFL). The inhibition ratio of lipid production was calculated through formula 1.

Measurement of the triglyceride content

Cells were seeded in 96-well plates. 3T3-L1 adipocyte monolayer was washed three times with phosphate-buffered saline (PBS) and then fixed for 30 min with 3.7% formaldehyde in PBS. Oil-Red-O (0.5%) in isopropanol was diluted with 2/3 volumes of water, filtered and added to the fixed cell monolayer for 1 h at room temperature. The cell monolayer was then washed with PBS, and the stained triglyceride droplets in the cells were visualized. Finally, the dye retained in the cells was eluted with isopropanol and quantified by measuring the optical absorbance at 492 nm by a microplate reader (Labsystems Multiskan Ascent). The inhibition of lipid accumulation was evaluated by using triplicate assay.

Apoptosis assays

Chromatin Staining with Hoechst 33342

Cells were fixed with 3.7% para-formaldehyde for 30 min, and then stained with 10 μmol·L-1 Hoechst 33342 dye (Sigma) for 30 min in the dark. After staining, cells were observed by fluorescence microscopy (Carl Ziess Axiovert 40 CFL). Cells with bright blue fragmented nuclei showing condensation of chromatin were identified as apoptotic cells.

Flow cytometry

Phosphatidylserine exposed on the outside of the apoptotic cells was determined by anannexin V-fluorescein isothiocyanate (FITC) Apoptosis kit (KeyGene). In brief, to detect early apoptosis, late apoptosis, and necrosis induced by compound 1a, we plated the 3T3-L1 adipocytes at a density of 1 × 106 cells/dish in a 60-mm dish and exposed them for 24 h at 37°C. Cells were harvested by centrifugation and washed with ice-cold PBS twice; the cells were then stained with 20 μL of annexin V-FITC and 20 μL of PI at room temperature for 15 min in the dark. Annexin V-FITC and PI emissions were detected in the FL1 and FL2 channels of a FACScan flow cytometer (BD FACSC anto™), using emission filters of 525 nm and 575 nm. The percentages of distribution of normal cells and cells in early apoptosis, late apoptosis and necrosis were calculated by CellQuest software (BD Biosciences).

Statistical Analysis

Data are presented as the mean ± SD. Data were analyzed by one-way ANOVA using Statistical Package for Social Science (SPSS, Chicago, IL). Differences were considered to be significant at p < 0.05.

Results

Body mass (BM) and fat mass

After 4 weeks' induction, mice fed with HFD had 5.3% higher body weights compared with normal group fed with LFD (p < 0.05). The obese model was made successfully. Four-week treatment later, low dosage group and high dosage group had 6.86% and 12.33% lower body weights (p < 0.05) than model group respectively (Fig.2A). No obvious difference was found between normal group and high dosage group. As compound 1a dosage doubled, the weight loss compared with model group increased. The weight loss displayed dosage dependence.
Figure 2

Effects of compound 1a on C57BL/6J mice. A: Effects of compound 1a on the weight of the mice after treatment. B: Effects of compound 1a on the weight of the adipose tissue after treatment. Normal group: low fat diet; Model group: high fat diet; Low dosage group: high fat diet+50 mg·kg-1 compound 1a; High dosage group: high fat diet+100 mg·kg-1 compound 1a; Control group: high fat diet+200 mg·kg-1 Inositol Hexanicotinate. All values are mean ± SD (n = 10), * presents P < 0.05 compared with model group. ** presents P < 0.05 compared with normal group

White adipose tissue mass was also significantly increased by 148% in model group compared with normal group (p < 0.05) (Fig.2B). In response to compound 1a at high dosage, the adipose tissue weights in high dosage group were significantly decreased by 35.29% compared with the model group (p < 0.05). The result inferred that compound 1a inhibited HFD-induced body weight gain and adipose tissue mass in mice effectively.

Changes in lipid profiles

To determine whether compound 1a has beneficial effects on the circulating lipid profiles, we tested its effects on serum triglyceride and cholesterol levels. Compared with normal group, serum levels of triglycerides and total cholesterol in model group were increased by 21.32% (p < 0.05) and 164% (p < 0.05) respectively (Fig.3A). This result suggested that the high lipid model was made successfully. After treatment, compound 1a (high dosage) caused significant reductions in serum triglyceride and total cholesterol levels by 28% (p < 0.05) and 46% (p < 0.05) respectively, compared with model group. It was worthy noted that serum HDL-C in high dosage group was much higher than that in other groups (p < 0.05). Consequently, we believed that compound 1a suppressed lipid disorders through increasing HDL-C and depressing TG, thereby preventing hypertriglyceridemia and hypercholesterolemia.
Figure 3

Effects of compound 1a on serum lipids and leptin. A: Changes in TG, TC, LDL-C and HDL-C by compound 1a in high-fat diet fed obese mice. Compound 1a-treated mice had significantly lower serum concentration of triglycerides and higher HDL-C compared with high-fat diet alone. B: Effects of compound 1a on serum leptin. Serum leptin concentration was reduced by compound 1a in a concentration dependent manner. Normal group: low fat diet; Model group: high fat diet; Low dosage group: high fat diet+50 mg·kg-1 compound 1a; High dosage group: high fat diet+100 mg·kg-1 compound 1a; Control group: high fat diet+200 mg·kg-1 Inositol Hexanicotinate. All values are mean ± SD (n = 10), * presents P < 0.05 compared with model group. ** presents P < 0.05 compared with normal group.

Changes in serum leptin

The serum leptin level in model group was much higher than that in normal group (p < 0.05). The result implied that obesity mice accompanied with leptin resistance. Compound 1a (high dosage) caused significant reduction in serum leptin by 52.21% (p < 0.05) compared with model group and reduced serum leptin in a dose- dependent manner (Fig. 3B).

The results suggested that compound 1a could improve leptin resistance induced by obesity.

Hepatic lipid accumulation

The hepatic accumulation of lipid was observed in mice hepatic tissue slice by light microscopy. Mice in model group showed considerable hepatic lipid accumulation compared with that in normal group.

The mice hepar in high dosage group showed considerably lower hepatic lipid accumulation than in model group. As shown in Fig.4, the triglyceride droplets appeared in mice hepar were almost completely disappeared by compound 1a treatment. Thus, the result suggested that compound 1a could increase fat catabolism in the liver and inhibited hepatic lipid accumulation.
Figure 4

Inhibition of hepatic lipid accumulation by compound 1a in high-fat diet-fed obese mice. Histological analyses of hepatic lipid accumulation. Representative HE-stained liver sections are shown (original magnification 200×). A presents the normal hepatocyte appearance. High fat diet induced hepatocytes necrosis was shown in B. After the treatment of compound 1a, necrosis hepatocytes are reduced, especially in D. Small lipid drops were seen C. There were obvious lipid drops in E. A: low fat diet (normal group); B: high fat diet (model group); C: high fat diet+50 mg·kg-1 compound 1a (low dosage group); D: high fat diet+100 mg·kg-1 compound 1a (high dosage group); E: high fat diet+200 mg·kg-1 Inositol Hexanicotinate (control group).

Proliferation and differentiation of 3T3-L1

To determine whether compound 1a inhibited the cell viability of 3T3-L1 preadipocytes, cells were treated with four various doses of compound 1a and Inositol Hexanicotinate. Cell viability was estimated by the MTT assay and compound 1a treatment inhibited cell growth in a dose-dependent manner (Fig.5). When it reached 0.1 mmol·L-1, the viability was suppressed by 28.31%. To examine the effect of compound 1a on adipogenesis, 3T3-L1 preadipocytes were treated with adipogenic hormone mixture in the absence or presence of compound 1a. During 3T3-L1 cell differentiation, the number of larger lipid droplets in cells decreased. After 10 days, triglyceride content of 3T3-L1 cells treated with compound 1a was measured. It exhibited a significant dose-dependent decrease in the intracellular accumulation of triacylglycerol under Oil-Red-O staining (Fig.6). However, there was no significant difference between Inositol Hexanicotinate group and the control group.
Figure 5

Effect of compound 1a on the inhibition of cell viability in 3T3-L1 preadipocytes. After the influence reached 80%, 3T3-L1 preadipocytes were incubated with compound 1a, at the indicated concentration (1 × 10-7, 1 × 10-6, 1 × 10-5, 1 × 10-4mol L-1) for 48 h; growth rate was assessed by MTT assay. The inhibition ratio was calculated by formula 1. All values are mean ± SD (n = 3)

Figure 6

Effect of compound 1a on lipid adipogenesis. A: Effect of compound 1a on lipid accumulation in 3T3-L1 adipocytes. At two days after confluence, 3T3-L1 cells were differentiated by MDI. At day 8 compound 1a was given to the cells at series of concentrations. Ten days after differentiation, we measured triglyceride content of 3T3-L1 cells treated with compound 1a by Oil-Red-O staining. The inhibition ratio was calculated by formula 1. B: Effect of vehicle, compound 1a, Inositol Nicotinate on the lipid accumulation by Oil-Red-O staining. Images of the stained lipid droplets were collected on a fluorescence microscope. Lipid accumulation was significantly decreased treated by compound 1a. All values are mean ± SD (n = 3).

Apoptosis assays

An increase in apoptotic nuclei in both preadipocytes and mature adipocytes treated with 0.1 mmol·L-1 compound 1a were evident from photos of Hoechst-33342 staining (data not show). We suggested that apoptosis was induced by the compound 1a both in preadipocytes and in mature adipocytes.

To quantify the modes of cell death induced by compound 1a, 3T3-L1 preadipocytes and adipocytes were treated with series concentration of compound 1a(1 × 10-4, 1 × 10-5, 1 × 10-6, 1 × 10-7mol·L-1) for 24 h, were subjected to simultaneous staining with annexin V-FITC and PI, and were analyzed by FACScan flow cytometry. Annexin V-FITC/PI double-staining analysis demonstrated that the number of normal cells decreased in a dose-dependent manner exposed to compound 1a. The apoptotic cells, including early apoptosis and late apoptosis, were increased in a dose-dependent manner. When the compound 1a concentration elevated to 0.1 mmol·L-1, the percentage of cells in G3 decreased from 52.2% to 35.9% (preadipocytes) and from 86.1% to 72% (adipocytes), respectively; cells in G2 and G4, including early and late apoptosis, increased from 47.8% to 64.1% (preadipocytes) and from 13.3% to 27.4%(adipocytes), respectively (Table.1, Fig.7).
Table 1

Preadipocytes(table.1-1) and mature adipocytes(table.1-2) were incubated in vitro without or with 1 × 10-7, 1 × 10-6, 1 × 10-5, 1 × 10-4 mol·L-1 of compound 1a for 24 h and analyzed by Annexin V/PI cell viability assay.

1-1

%Parent

blank

1*10-7

1*10-6

1*10-5

1*10-4

Q1

1.7

2.5

1.8

2.8

1.5

Q2

39.0

38.5

39.2

41.6

43.2

Q3

50.5

47.6

46.7

39.5

34.4

Q4

8.8

11.2

12.4

16.0

20.9

1-2

Q1

0.5

0.2

0.5

0.1

0.5

Q2

1.8

1.3

1.5

1.4

2.7

Q3

86.1

85.8

85.4

81.2

72

Q4

11.5

12.8

12.6

17.3

24.7

Apoptotic (Q4+Q2) cells were identified and expressed as a percentage of total dead cells.

Figure 7

Apoptosis ratios (apoptosis cell number in treatment group/apoptosis cell number in blank group) after 24 h were shown in this picture. With the concentration increase, the apoptosis ratio was raised both in preadipocytes and mature adipocytes. The phenomenon was more notable in mature adipocytes induced by 1 × 10-4 mol·L-1 compound 1a, whose apoptosis ratio reached almost 206% compared with DMSO group.

The result demonstrated that compound 1a could induce apoptosis of both preadipocytes and mature adipocytes.

Discussion

Obesity is the result of an energy imbalance caused by an increased ratio of caloric intake to energy expenditure. In conjunction with obesity, related metabolic disorders such as dyslipidemia, atherosclerosis, and type 2 diabetes have become global health problems. As well as diet and exercise, some drugs are useful for weight reduction. To date, only sibutramine and orlistat have been approved for use, though both have poor outcomes and are not so well tolerated [22]. Rimonabant is a selective CB1 receptor blocker which has been proven effective in achieving substantial weight loss and in reducing triglyceride levels and glycohemoglobin. It has also been shown to increase HDL cholesterol levels in obese patients and specifically in patients with diabetes [2325]. However, it was reported that sibutramine, orlistat and Rimonabant had several serious adverse effects in clinic, including gastrointestinal adverse effect and significant unfavorable effects on cardiovascular system. As a result, much safer therapeutic is necessary. In addition, there has been a large increase in the use of complementary treatments such as herbal remedies in the treatment of these diseases over the past decade [26].

We observed that mice fed with HFD supplemented with compound 1a for 4 weeks had lower levels of serum triglycerides, LDL-C and higher levels of HDL-C compared with mice fed with HFD alone, which indicated that compound 1a efficiently regulated triglyceride and cholesterol metabolism in obese mice. Thus, compound 1a may be beneficial for treating patients with hypercholesterolemia and hypertriglyceridemia.

Lipids are transported in the body by a sophisticated lipoprotein transport system. Lipoproteins are divided into 5 main classes according to their density: chylomicrons, VLDL-C, IDL-C, LDL-C and HDL-C [27]. LDL-C is a risk factor for CAD. The antagonist of LDL-C is HDL-C. It collects cholesterol from body tissues and returns it to the liver. As a result, HDL-C cholesterol levels are inversely related to this risk [28]. Compound 1a was determined to effectively in elevating HDL-C. Thus, we tentatively put forward that compound 1a was effective in reversing coronary artery disease.

In parallel with its effect on serum TG, mice fed with HFD supplemented with compound 1a had significantly lower adipose tissue mass and body weight gain than that fed with HFD alone. This correlated with reports showed that the lipids in adipose tissue were largely derived from circulating triglycerides, especially during HFD feeding [29, 30] and that the reductions in serum TG also led to decreased adipose tissue mass [3133].

Increased lipid accumulation in hyperlipidemic rats and mice may be due to increased levels of triglyceride depots in the liver [33]. Histological analysis in our research showed that HFD-fed mice had considerable hepatic lipid accumulation. After 4-week treatment with compound 1a, hepatic lipid accumulation disappeared (high dosage group). Long term hepatic lipid accumulation would cause fatty liver. Thus the result suggested that compound 1a could recover fatty liver induced by lipid accumulation.

Leptin, a 167-amino acid protein, is synthesized and secreted mainly by adipose tissue [34, 35]. Adipose tissue produces the hormone leptin in approximate proportion to fat stores. Circulating leptin communicates the level of energy reserves in the periphery to the central nervous system (CNS) in order to suppress food intake and permit energy expenditure [34, 3638]. Peripheral administration of exogenous leptin results in a specific reduction in body fat mass with no change in lean mass in experimental animals [39] or in obese humans on a weight-reducing diet [40], but elevated concentrations of endogenous leptin do not appear to be capable of preventing, or reversing, the accumulation of adipose tissue during, or after, the development of obesity [41]. Several authors have reported that aging [42, 43] or the consumption of a HFD [4446] results in the development of leptin resistance in rodents, measured as a failure of leptin either to inhibit food intake or to induce weight loss. Increased circulating leptin, a marker of leptin resistance, is common in obesity and independently associates with insulin resistance [47] and CVD [4851] in humans. In our study, Serum leptin in model group was raised during the induction of HFD to 694.76 pg·mL-1. After the treatment of 100 mg·kg-1 compound 1a, the serum leptin was reduced to 52.21% compared with model group. It suggested that compound 1a was effective to leptin resistance induced by HFD in mice.

The possible mechanisms for the treatment of obesity are as follows: balance energy intake and expenditure, reduce preadipocyte differentiation, decrease lipogenesis, increase lipolysis and induce adipocyte apoptosis [52]. Adipocytes play an important role in lipid homeostasis and energy balance by relating to triglyceride storage and free fatty acids release. Adipocyte differentiation and the amount of fat accumulation are associated with the occurrence and development of obesity [53]. Moreover, adipocyte produces and secretes dozens of factors such as leptin, adiponectin, resistin, visfatin, TNF-α, and IL-6, which participate in energy metabolism of adipose tissue itself and the whole body either in an auto/paracrine or an endocrine fashion [54]. For these reasons, anti-obesity works have been conducted in 3T3-L1 adipocytes.

Anti-obesity effect of compound 1a in the 3T3-L1 cell model was measured in our study. Any reduction in adipocyte number can result from preadipocyte or adipocyte apoptosis, as well as adipocyte dedifferentiation [55]. In this study we investigated the effects of compound 1a on adipocyte viability, apoptosis and lipid accumulation during adipogenesis in 3T3-L1 cells. We found that compound 1a inhibited cell viability and enhanced apoptosis in both pre- and mature adipocytes. Correspondingly, the lipid accumulation was suppressed during the differentiation process. As to in vivo experiment, the adipose was depauperated, which was coincident with the weight and adipose tissue loss.

Lipolysis is a property of mature, differentiated adipocytes. Adipocyte maturation requires an elaborate sequence of events associated with specific patterns of transcription factors at different phases of differentiation [56]. Mature adipocytes have massive TG storage compared with any other tissue, despite having a well-developed lipolytic capacity. Conversely, a decrease of adipocyte differentiation, which by definition is associated with reduction of the lipid droplet volume, will transiently be accompanied by a net increase in lipolysis, and this is one potential mechanism for increasing lipolysis. As an important component in the network of lipid energy metabolism, adipocyte lipolysis is positioned to affect the fat content of liver, muscle, heart and kidney in obesity.

In conclusion, the results of the in vivo and in vitro study show that compound 1a regulates serum lipid profiles, decreases adipose tissue mass and body weight gain by inducing adipocyte apoptosis. The compound 1a may be used to treat obese patients with hypercholesterolemia and hypertriglyceridemia. The adipocyte apoptosis mechanism induced by compound 1a will be further researched.

Abbreviations

CAD: 

Coronary Artery Disease

CNS: 

Central nervous system

CVD: 

Cardiovascular disease

DEX: 

Dexamethasone

DMEM: 

Dulbecco's modified Eagle's medium

FBS: 

Fetal bovine serum

HFD: 

High fat diet

HDL-C: 

High density lipoprotein cholesterol

HE: 

Hematoxylin and eosin

IBMX: 

3-Isobutyl-1-methylxanthine

IL-6: 

Interleukin-6

LDL-C: 

Low density lipoprotein cholesterol

LFD: 

Low fat diet

MTT: 

3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide

PBS: 

Phosphate buffered saline

TC: 

Total cholesterol

TG: 

Triglyceride

TNF-α: 

Tumor necrosis factor-α.

Declarations

Acknowledgements

The authors thank department of Medical Chemistry in China Pharmaceutical University for their assistance in the preparations of the compound 1a.

Authors’ Affiliations

(1)
Nanjing Brain Hospital affiliated to Nanjing Medical University
(2)
Department of Pharmacy English, China Pharmaceutical University
(3)
Department of Medical Chemistry, China Pharmaceutical University

References

  1. Formiguera X, Canton A: Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol. 2004, 18: 1125-1146.View ArticlePubMedGoogle Scholar
  2. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol, Metab. 2004, 89: 2595-2600. 10.1210/jc.2004-0372.View ArticleGoogle Scholar
  3. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J, Hartzell DL, Hamrick MW, Baile CA: Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr. 2006, 136: 409-414.PubMedGoogle Scholar
  4. Vettor R, Rossato M: The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from Rimonabant In Obesity (RIO) trials. International Congress Series. 2007, 1303: 146-154. 10.1016/j.ics.2007.03.025.View ArticleGoogle Scholar
  5. Padwal R, Majumdar S: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007, 369: 71-77. 10.1016/S0140-6736(07)60033-6View ArticlePubMedGoogle Scholar
  6. Sayin T, Güldal M: Sibutramine: Possible cause of a reversible cardiomyopathy. International Journal of Cardiology. 2005, 99: 481-482. 10.1016/j.ijcard.2003.11.060View ArticlePubMedGoogle Scholar
  7. Lin J, Della-Fera MA, Baile CA: Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res. 2005, 13: 982-990. 10.1038/oby.2005.115View ArticlePubMedGoogle Scholar
  8. Xie L, O'Reilly C: Adiponectin and leptin are secreted through distinct trafficking pathways in adipocytes. Biochimica et Biophysica Acta. 2008, 1782: 99-108.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Fasshauer M, Kralisch S: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications. 2003, 301: 1045-1050. 10.1016/S0006-291X(03)00090-1View ArticlePubMedGoogle Scholar
  10. Araki S, Dobashi K: N-acetylcysteine attenuates TNF-α induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sciences. 2006, 79: 2405-2412. 10.1016/j.lfs.2006.08.004View ArticlePubMedGoogle Scholar
  11. Tanaka Masaki, Nozaki Maiko: Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochemical and Biophysical Research Communications. 2007, 359: 194-201. 10.1016/j.bbrc.2007.05.096View ArticlePubMedGoogle Scholar
  12. Hargrave KM, Meyer BJ, Li C, Azain MJ, Baile CA, Miner JL: Influence of dietary conjugated linoleic Acid and fat source on body fat and apoptosis in mice. Obes Res. 2004, 12: 1435-1444. 10.1038/oby.2004.180View ArticlePubMedGoogle Scholar
  13. Kim OK: Ginseng saponin-Re and Coix lachrymajobi var. mayuen regulate obesity related genes expressions, TNF-alpha, leptin, lipoprotein lipase and resistin in 3T3-L1 adipocytes. Korean J Life Sci. 2007, 17: 1523-1532.View ArticleGoogle Scholar
  14. Cho EJ, Rahman A, Kim SW, Baek YM, Hwang HJ, Oh JY, Hwang HS, Lee SH, Yun JW: Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes. J Microbiol Biotechnol. 2008, 18: 80-87.PubMedGoogle Scholar
  15. Tang QQ, Otto TC, Lane MD: Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA. 2003, 100: 44-49. 10.1073/pnas.0137044100PubMed CentralView ArticlePubMedGoogle Scholar
  16. Saltiel AR, Kahn CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001, 414: 799-806. 10.1038/414799aView ArticlePubMedGoogle Scholar
  17. Cederroth CR, Nef S: Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol. 2009, 304 (1-2): 30-42. 10.1016/j.mce.2009.02.027View ArticlePubMedGoogle Scholar
  18. Song WO, Chun OK, Hwang I, Shin HS, Kim BG, Kim KS, Lee SY, Shin D, Lee SG: Soy Isoflavones as Safe Functional Ingredients. J Med Food. 2007, 10: 571-580. 10.1089/jmf.2006.0620View ArticlePubMedGoogle Scholar
  19. Veitch NC: Isoflavonoids of the Leguminosae. Nat Prod Rep. 2007, 24: 417-464. 10.1039/b511238aView ArticlePubMedGoogle Scholar
  20. Ørgaard A, Jensen L: The Effects of Soy Isoflavones on Obesity. Exp Bio Med. 2008, 233: 1066-1080. 10.3181/0712-MR-347.View ArticleGoogle Scholar
  21. Havel PJ: Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc. 2000, 59: 359-371. 10.1017/S0029665100000410View ArticlePubMedGoogle Scholar
  22. Jason CG, Halford : Pharmacotherapy for obesity. Appetite. 2006, 46: 6-10.View ArticleGoogle Scholar
  23. Scheen AJ, Finer N, Hollander P, Jensen MD, van Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patient with type 2 diabetes: a randomized controlled study. Lancet. 2006, 368: 1660-1672. 10.1016/S0140-6736(06)69571-8View ArticlePubMedGoogle Scholar
  24. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet. 2007, 370: 1706-1713. 10.1016/S0140-6736(07)61721-8View ArticlePubMedGoogle Scholar
  25. Levy P, Fried M, Santini F, Fines : The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg. 2007, 17: 1248-1256. 10.1007/s11695-007-9214-zView ArticlePubMedGoogle Scholar
  26. Ono Y, Hattor E: Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats. Journal of Ethnopharmacology. 2006, 106: 238-244. 10.1016/j.jep.2005.12.036View ArticlePubMedGoogle Scholar
  27. Schittmayer M, Birner-Gruenberger R: Functional proteomics in lipid research: Lipases, lipid droplets and lipoproteins. Proteomics. 2009,Google Scholar
  28. Rezaee F, Casetta B: Proteomic analysis of high-density lipoprotein. Proteomics. 2006, 2: 721-730. 10.1002/pmic.200500191.View ArticleGoogle Scholar
  29. Lupien P, Brun D, Gagne C, Moorjani S, Bielman P, Julien P: Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. The Canadian Journal of Cardiology. 1991, 7: 27-33.PubMedGoogle Scholar
  30. Fruchart JC, Brewer HB, Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. The American Journal of Cardiology. 1998, 81: 912-917. 10.1016/S0002-9149(98)00010-1View ArticlePubMedGoogle Scholar
  31. Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT: Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Experimental and Molecular Medicine. 2002, 34: 485-492.View ArticleGoogle Scholar
  32. Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT: Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochemical and Biophysical Research Communications. 2003, 302: 29-34. 10.1016/S0006-291X(03)00088-3View ArticlePubMedGoogle Scholar
  33. Jeong S, Han M, Lee H, Kim M, Nicol CJ, Kim BH, Choi JH, Oh GT, Yoon M: Effects of fenofibrate on high fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004, 53: 1284-1289. 10.1016/j.metabol.2004.05.003View ArticlePubMedGoogle Scholar
  34. Friedman JM, Halas JL: Leptin and the regulation of body weight in mammals. Nature. 1998, 395: 763-770. 10.1038/27376View ArticlePubMedGoogle Scholar
  35. Margetic S, Gazzola C, Pegg GG, Hill RA: Leptin: a review of its peripheral actions and interactions. Int J obes Relat, Metab Disord. 2002, 26: 1407-1433. 10.1038/sj.ijo.0802142.View ArticleGoogle Scholar
  36. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB: Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol. 2005, 493: 63-71. 10.1002/cne.20786View ArticlePubMedGoogle Scholar
  37. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW: Central nervous system control of food intake and body weight. Nature. 2006, 443: 289-295. 10.1038/nature05026View ArticlePubMedGoogle Scholar
  38. Bates SH, Myers MG: The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab. 2003, 14: 447-452. 10.1016/j.tem.2003.10.003View ArticlePubMedGoogle Scholar
  39. Chen Y, Heiman M: Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept. 2000, 92: 113-119. 10.1016/S0167-0115(00)00157-9View ArticlePubMedGoogle Scholar
  40. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999, 282: 1568-1575. 10.1001/jama.282.16.1568View ArticlePubMedGoogle Scholar
  41. Considine RV, Caro JF: Leptin and the regulation of body weight. Int J Biochem Cell Biol. 1997, 29: 1255-1272. 10.1016/S1357-2725(97)00050-2View ArticlePubMedGoogle Scholar
  42. Jacobson L: Middle-aged C57BL/6 mice have impaired responses to leptin that are not improved by calorie restriction. Am J Physiol. 2002, 282: E786-793.View ArticleGoogle Scholar
  43. Scarpace PJ, Matheny M, Zhang Y, Tumer N, Frase CD, Shek EW: Central leptin gene delivery evokes persistent leptin signal transduction in young and aged-obese rats but physiological responses become attenuated over time in aged-obese rats. Neuropharmacology. 2002, 42: 548-561. 10.1016/S0028-3908(02)00003-5View ArticlePubMedGoogle Scholar
  44. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS: Two defects contribute to hypothalamic leptin resistance in mice with dietinduced obesity. J Clin Invest. 2000, 105: 1827-1832. 10.1172/JCI9842PubMed CentralView ArticlePubMedGoogle Scholar
  45. Lin L, Martin R, Schaffhauser AO, York DA: Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol. 2001, 280: 504-509.Google Scholar
  46. Lin S, Thomas TC, Storlien LH, Huang XF: Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord. 2000, 24: 639-646. 10.1038/sj.ijo.0801209View ArticlePubMedGoogle Scholar
  47. Mantzoros CS, Liolios AD, Tritos NA: Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res. 1998, 6: 179-186.View ArticlePubMedGoogle Scholar
  48. Soderberg S, Ahren B, Jansson JH: Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999, 246: 409-418. 10.1046/j.1365-2796.1999.00571.xView ArticlePubMedGoogle Scholar
  49. Wallace AM, McMahon AD, Packard CJ: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001, 104: 3052-3056. 10.1161/hc5001.101061View ArticlePubMedGoogle Scholar
  50. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK: Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004, 44: 1819-1824. 10.1016/j.jacc.2004.07.050View ArticlePubMedGoogle Scholar
  51. Reilly MP, Iqbal N, Schutta M: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Meta. 2004, 89: 3872-3878. 10.1210/jc.2003-031676.View ArticleGoogle Scholar
  52. Evans M, Lin X, Odle J, McIntosh M: Trans-10, cis-12 conjugated linoleic acid increases fatty acid oxidation in 3T3-L1 preadipocytes. J Nutr. 2002, 132: 450-455.PubMedGoogle Scholar
  53. Jeon T, Hwang SG, Hirai S, Matsui T, Yano H, Kawada T, Lim BO, Park DK: Red yeast rice extracts suppress adipogenesis by down-regulating adipogenic transcription factors and gene expression in 3T3-L1 cells. Life Sci. 2004, 17: 3195-3203. 10.1016/j.lfs.2004.06.012.View ArticleGoogle Scholar
  54. Zou C, Shao J: Role of adipocytokines in obesity-associated insulin resistance. Journal of Nutritional Biochemistry. 2008, 19: 277-286. 10.1016/j.jnutbio.2007.06.006View ArticlePubMedGoogle Scholar
  55. Prins JB, O'Rahilly S: Regulation of adipose cell number in mature adipocytes. Clin Sci (Lond). 1997, 92: 3-11.View ArticleGoogle Scholar
  56. Farme SR: Transcriptional control of adipocyte formation. Cell Metab. 2006, 4: 263-273. 10.1016/j.cmet.2006.07.001View ArticleGoogle Scholar

Copyright

© Yao et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement